Compare BON & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BON | APRE |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9M | 11.5M |
| IPO Year | 2020 | 2019 |
| Metric | BON | APRE |
|---|---|---|
| Price | $1.18 | $0.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.10 |
| AVG Volume (30 Days) | 20.1K | ★ 104.4K |
| Earning Date | 01-23-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $390.73 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $0.55 |
| 52 Week High | $3.39 | $2.22 |
| Indicator | BON | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 45.17 | 45.27 |
| Support Level | $1.16 | $0.57 |
| Resistance Level | $1.33 | $0.83 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 33.33 | 37.74 |
Bon Natural Life Ltd focuses on the manufacturing of personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers, natural health supplements such as powder drinks and bioactive food ingredient products mostly used as food additives and nutritional supplements by its customers. It has developed four technology platforms for large-scale separation, safety improvement, activity enhancement, and functional compounding of natural products. The company's offerings include Fragrance compounds, Health supplements, and Bioactive food ingredients. The company generates revenue from the sale of its products, the majority derived from the sale of Fragrance compounds, which include natural compounds extracted from plants for cosmetic applications.
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.